Introduction {#sec1-1}
============

Cardiovascular diseases (CVD) are the most common cause of morbidity and mortality in many countries. According to the World Health Organization (WHO), cardiovascular diseases account for 16.7 million deaths per year ([@ref1]).

Atherosclerosis is a condition in which an artery wall thickens as a result of the increase of total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-c). A complex chronic inflammatory and metabolic disease is caused largely by the accumulation of macrophages and white blood cells and is promoted by LDL ([@ref2]).

HDL has some physiological activities. For example, mature HDL presents a hydrophobic core composed of cholesteryl esters and TGs with proteins embedded in a lipid monolayer collected mainly of phospholipids and free cholesterol. HDL contains several apolipo-proteins including apolipoprotein A-I (apoA-I) and apoA-II (the two main proteins) and a large number of less abundant proteins counting apoCs, apoE, apoD, apoJ ([@ref3], [@ref4]).

The most relevant function of HDL is to promote the efflux of excess cholesterol from peripheral tissues to the liver for excretion; a pathway known as reverse cholesterol transport ([@ref5], [@ref6]). The efflux of cholesterol is important for maintaining cellular cholesterol homeostasis ([@ref7]).

Egg yolk contains high amount of HDL. Egg yolk HDL can be used to treat cardiovascular disease. The focus of egg yolk HDL treatment has been on its favorable actions in increasing HDL-c and reducing LDL-c, very low density lipoprotein cholesterol (VLDL-c), and lipoproteins ([@ref8]).

On the basis of efficacy of Egg yolk HDL on the treatment of cardiovascular diseases and its other beneficial effects, the purpose of this study was to assess the clinical utility of egg yolk HDL on the lipid profiles and atherosclerosis plaque size in rabbits.

Materials and Methods {#sec1-2}
=====================

Preparation of egg yolk proteins {#sec2-1}
--------------------------------

Eggs were purchased from Simorgh Company. To separate the egg yolk proteins, the eggs were homogenized in 5 volume of 0.15 M phosphate buffer (pH 7.4) containing 3.4 Mm ethylenediaminetetraacetic acid (EDTA) and 2 Mm Na~2~HPO~4~ and NaH~2~PO~4~. The homogenate was centrifuged at 8500 rpm for 15 min at 4°C. After centrifugation, a clear supernatant was separated from a floating oily and a pellet. The clear supernatant was called "egg yolk proteins" and submitted for the isolation of lipoproteins ([@ref9]).

Isolation of egg yolk lipoproteins {#sec2-2}
----------------------------------

Potassium bromide (KBr) was added to the egg yolk proteins to a final concentration of 8.9 g KBr/20 ml solution (44.5%). The solution was placed in a centrifuge tube and overlaid with 20 ml 0.75% NaCl. The tube was centrifuged (Beckman, model L-90) at 50,000 rpm for 6 hr at 15 °C. After centrifugation, fractions were collected and the density was determined by refractometry. The floating HDL fraction (1.15 g/ml ≤ density (d) ≤ 1.25 g/ml) was separated from the bottom fraction (lipid-free protein) and adjusted to a density of 1.30 g/ml by the addition of solid KBr in a final volume of 20 ml. The solution was then located in centrifuge tube, overlaid with 20 ml 22% KBr in 0.75% NaCl, and centrifuged at 50,000 rpm for 6 hr at 15 °C. The floating LDL fraction (1.03 g/ml ≤ d ≤ 1.10 g/ml) was brought to final KBr concentration of 22% and overlaid in a centrifuge tube with 20 ml 0.75% NaCl. The separated lipoproteins were dialyzed against 0.15 M NaCl-10 Mm phosphate buffer (pH 7.4).

Animals and diets {#sec2-3}
-----------------

Thirty adult New Zealand White male rabbits weighing 2-2.5 kg were used in this study (Pasteur Institute, Tehran, Iran). The animals were maintained in individual cages at 20-25 °C temperature and humidity level of 55-65%, under a 12 hr light-dark cycle. They were fed on a standard rabbit's diet (Javane Khorasan, Mashhad, Iran) consisted of 10% protein, 40-50% carbohydrates, 2% vegetable fat, and 15-25% fiber.

Animals were fasted for 12-14 hr and venous blood samples were taken to determine baseline levels. Then they were randomly separated into five groups (n=6). Each group received one of the five experimental diets: A; normal diet for 4 weeks (as control group), B;3% of cholesterol diet for 4 weeks (as hypercholesterolemic group), C; hypercholesterolemic rabbits that received egg yolk HDL in high dose (400 mg/kg) by gavage daily, D; hypercholesterolemic rabbits that received egg yolk HDL in low dose (100 mg/kg) by gavage daily, and E; normal diet rabbits that received egg yolk HDL in dose (200 mg/kg) by gavage daily.

The cholesterol rich diet was specially fabricated for the experiments, composed of additional 3% cholesterol added to the standard diet, and the rabbits were fed for 4 weeks. Then, egg yolk HDL was gavaged to rabbits for 6 weeks in groups C, D, and E.

Biochemical analysis {#sec2-4}
--------------------

After a 12-14hr fasting, blood samples were collected from the femoral artery of animals' leg at the baseline and every two weeks until the end of the study. For obtaining the serum, blood samples were centrifuged at 3500 rpm for 20 min. Serum TC, TG, and HDL-C were measured by using standard enzymatic methods (Pars Azmoon Company, Iran) and then were analyzed with an auto analyzer system (Hitachi 902, Japan) ([@ref10]).

Preparation of tissue samples {#sec2-5}
-----------------------------

At the end of the experiment, all rabbits were anesthetized via inhalation of ether and thoracic aorta was harvested (from the left subclavian artery to the diaphragm). The aortic plaques were assessed blindly; the thoracic aortas were fixed in 10% formalin for 2 days. After tissue processing and embedding in paraffin, 5μm sections were prepared using a rotary microtome (Leitz 1512, Germany), and dried on a hot plate at 50--55 °C for 30 min; H&E were used to stain the tissue sections. The preparations were examined under light microscope using ×10 and ×40 objective lenses (UPlanFI, Japan) and images were transferred to computer using a high-resolution camera (BX51, Japan). All sections were digitally photographed and the surface areas of atherosclerotic plaque were estimated using a 1000 μm 2 counting frame. Plaque surface area was measured by point grid overlays A= P×A(p); A= surface area, P = no of test points, and A(p)= area associated with one point in the grid (50 mm^2^). Ten sections including atherosclerotic plaque from each aorta were chosen and analyzed.

Statistical analysis {#sec2-6}
--------------------

Values were expressed as mean±SEM. Statistical analysis was performed with SPSS (version 13). Statistic calculations were carried out with One Way analysis of variance (ANOVA) for multiple pair wise comparisons of groups. It was followed by Tukey test. A significant difference was defined as *P*-value \<0.05.

Results {#sec1-3}
=======

Biochemistry: serum lipid profiles {#sec2-7}
----------------------------------

### Serum TC {#sec3-1}

[Figure 1](#F1){ref-type="fig"} illustrates that the baseline serum levels of TC in group A and other groups were similar. Serum TC significantly increased in group B compared to group A in week 2 until week 12 (*P*-value \<0.05). Serum levels of TC in groups B, C, and D that fed cholesterol diet from 2^nd^ to 6^th^ week significantly increased than group A and E (*P*-value \< 0.005). In addition, there was a significant difference in the serum level of TC between the groups C, D, and E compared to group B during 8 to 12 weeks following egg yolk HDL treatment (*P*-value \< 0.05) (Figure and [Table 1](#T1){ref-type="table"} show details).

![Total cholesterol in five groups of A, B, C, D, and E. Group A: normal group, B: only atherosclerotic, C: atherosclerotic and gavaged dose 1 (400 mg/dl), D: atherosclerotic and gavaged dose 2 (100 mg/dl), E: only gavaged dose 3(200 mg /dl). Values are expressed as mean±SEM. \* *P*-value\< 0.05, \*\* *P*-value\< 0.01, and \*\*\**P*-value\<0.005. \# *P*-value\< 0.05, \#\# *P*-value\< 0.01, and \#\#\# *P*-value\<0. (\* versus group A) (\#versus group B)](IJBMS-18-343-g001){#F1}

###### 

The lipid profiles of groups A, B, C, D, and E measured in the different periods of the experiment (mg/dl)

  Column1       W0         W2                                       W4                                      W6                                     W8                                     W10                                                                W12
  ------------- ---------- ---------------------------------------- --------------------------------------- -------------------------------------- -------------------------------------- ------------------------------------------------------------------ ---------------------------------------
  Cholesterol                                                                                                                                                                                                                                                
   Group A      82.5025    42.78633                                 87.85873                                91.31583                               79.889                                 70.77897                                                           60.12247
   Group B      68.45821   1048.2[\*\*\*](#t1n3){ref-type="fn"}     723.33[\*\*\*](#t1n3){ref-type="fn"}    499.21[\*\*\*](#t1n3){ref-type="fn"}   280.381[\*\*](#t1n2){ref-type="fn"}    191.9155[\*](#t1n1){ref-type="fn"}                                 284.5417[\*](#t1n1){ref-type="fn"}
   Group C      82.91348   884.7817[\*\*\*](#t1n3){ref-type="fn"}   430.3365[\*](#t1n1){ref-type="fn"}      192.049[\#](#t1n4){ref-type="fn"}      134.8423[\#](#t1n4){ref-type="fn"}     108.9495                                                           81.35233
   Group D      73.275     903.4[\*\*\*](#t1n3){ref-type="fn"}      552.829[\*\*\*](#t1n3){ref-type="fn"}   267.8918[\#](#t1n4){ref-type="fn"}     170.305                                111.0195                                                           73.24817[\#](#t1n4){ref-type="fn"}
   Group E      51.65467   124.86[\#\#\#](#t1n6){ref-type="fn"}     78.145[\#\#\#](#t1n6){ref-type="fn"}    67.051[\#\#\#](#t1n6){ref-type="fn"}   84.50933[\#](#t1n4){ref-type="fn"}     70.33183[\#](#t1n4){ref-type="fn"}                                 49.52483[\#](#t1n4){ref-type="fn"}
    HDL                                                                                                                                                                                                                                                      
   Group A      46.8703    35.622                                   38.7557                                 41.8708                                38.5748                                37.7126                                                            38.8258
   Group B      44.20033   77.04633                                 43.49133                                52.158                                 25.049                                 38.64                                                              26.20467
   Group C      53.31933   62.81183                                 50.753                                  50.75817                               57.078[\#\#\#](#t1n6){ref-type="fn"}   84.2[\#\#\#](#t1n6){ref-type="fn"}[\*\*\*](#t1n3){ref-type="fn"}   52.19[\*\*\*](#t1n3){ref-type="fn"}
   Group D      49.02917   40.05567                                 40.91783                                45.48317                               58.67[\#\#\#](#t1n6){ref-type="fn"}    74.36[\#\#](#t1n5){ref-type="fn"}[\*\*](#t1n2){ref-type="fn"}      45.943[\*\*](#t1n2){ref-type="fn"}
   Group E      49.60533   66.9445                                  66.38883[\*](#t1n1){ref-type="fn"}      32.9935                                48.76633[\#](#t1n4){ref-type="fn"}     44.30583                                                           31.4114
    TG                                                                                                                                                                                                                                                       
   Group A      127.6217   75.04567                                 59.45367                                103.014                                86.83639                               81.08606                                                           77.40177
   Group B      150.1043   397.4683                                 213.618[\*\*\*](#t1n3){ref-type="fn"}   195.9492                               92.90767                               248.898[\*\*\*](#t1n3){ref-type="fn"}                              251.661[\*\*\*](#t1n3){ref-type="fn"}
   Group C      148.6758   385.5633[\*](#t1n1){ref-type="fn"}       129.3335                                87.61017                               74.97483                               137.394[\#\#\#](#t1n6){ref-type="fn"}                              253.731[\*\*\*](#t1n3){ref-type="fn"}
   Group D      124.9027   432.32[\*\*\*](#t1n3){ref-type="fn"}     118.1432[\#](#t1n4){ref-type="fn"}      118.2198                               167.5743                               208.434[\*\*\*](#t1n3){ref-type="fn"}                              252.398[\*\*\*](#t1n3){ref-type="fn"}
   Group E      101.3665   137.7457[\#](#t1n4){ref-type="fn"}       95.98467[\#](#t1n4){ref-type="fn"}      85.49833                               93.89433                               259.911[\*\*\*](#t1n3){ref-type="fn"}                              263.905

Group A: normal group, B: only atherosclerotic, C: atherosclerotic and gavaged dose 1 (400 mg/dl), D: atherosclerotic and gavaged dose 2 (100 mg/dl), E: only gavaged dose 3 (200 mg /dl). Results (mg/dl blood) are presented as mean±SEM.

*P*-value\<0.05,

*P*-value\<0.01, and

*P*-value\<0.005.

*P*-value\<0.05,

*P*-value\<0.01, and

*P*-value\<0.005 (\* versus group A) (\# versus group B). TC; total cholesterol, HDL-C; high density lipoprotein-cholesterol, TG; triglyceride

### Serum HDL {#sec3-2}

The baseline serum levels of HDL in all groups were similar. At the end of 8^th^ and 10^th^ weeks, the serum HDL was significantly increased by egg yolk HDL treatment in groups C and D (*P*-value \<0.01) compared to groups B and A. In addition, there was significant increase in the serum level of HDL in group E in comparison with group B at 8^th^ week (*P*-value \<0.05). In groups C and D serum levels of HDL at weeks 0 to 6 were significantly different compared to weeks 8 to 12 (*P*-value \<0.01). ([Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

![HDL-C in five groups of A, B, C, D, and E. Group A: normal group, B: only atherosclerotic, C: atherosclerotic and gavaged dose 1 (400 mg/dl), D: atherosclerotic and gavaged dose 2 (100 mg/dl), E: only gavaged dose 3 (200 mg /dl). Values are expressed as mean±SEM. \**P*-value \< 0.05, \*\**P*-value \< 0.01, and \*\*\**P*-value \< 0.005. \#*P*-value\< 0.05, \#\#*P*-value\< 0.01, and \#\#\#*P*-value\< 0. (\* versus group A) (\#versus group B)](IJBMS-18-343-g002){#F2}

### Serum TG {#sec3-3}

The baseline serum levels of TG in group A and other groups were similar. The serum TG level was significantly increased in 2^nd^ week that fed high cholesterol diet (group C). The serum TG level was significantly increased at 10^th^ and 12^th^ weeks in groups C, D, and E that fed egg yolk HDL compared to group A. At the end of 10^th^ and 12^th^ weeks, the serum TG was significantly decreased by egg yolk HDL treatment in group C (*P*-value\<0.01) compared to group B. In group E serum level of TG at 10^th^ and 12^th^ weeks was significantly increased compared to first weeks (*P*-value\<0.005) ([Figure 3](#F3){ref-type="fig"}).

![Triglycerides in five groups of A, B, C, D, and E. Group A: normal group, B: only atherosclerotic, C: atherosclerotic and gavaged dose 1 (400 mg/dl), D: atherosclerotic and gavaged dose 2 (100 mg/dl), E: only gavaged dose 3 (200 mg /dl). Values are expressed as mean±SEM. \**P*-value \< 0.05and \*\*\**P*-value \< 0.005. \#*P*-value \< 0.05 and \#\#\#*P*-value \< 0. (\*versus group A) (\#versus group B)](IJBMS-18-343-g003){#F3}

### Histological evaluation {#sec3-4}

Histopathological analysis: The thoracic aorta obtained from control rabbits revealed normal structural features histologically ([Figure 4-A](#F4){ref-type="fig"}). However, there was an increase in atherosclerotic plaques in the sub-endothelial layer of hypercholesterolemic aorta ([Figure 4-B](#F4){ref-type="fig"}). As shown in [Figure 4-B](#F4){ref-type="fig"}, the tunica intima layers were completely occupied with atherosclerotic plaques. The extracellular matrix, fibroblast-like cells, and smooth muscle cells in the atherosclerotic plaques were strongly present in the hypercholesterolemic animals.

![Hematoxylin & eosin stained arterial sections of thoracic aorta. An atherosclerotic plaque (P) can be observed in the group B in comparison to group A. These plaques occupy the intima layer completely in an aortic section which belongs to hypercholesterolemic rabbits. A: normal group, B: only atherosclerotic, C: atherosclerotic and gavaged dose 1 (400 mg/dl), D: atherosclerotic and gavaged dose 2 (100 mg/dl), E: only gavaged dose 3 (200 mg /dl), scale bars: 500 µm. ×20 ( ![](IJBMS-18-343-g004.jpg) atherosclerotic plaque) ( ![](IJBMS-18-343-g005.jpg) medial layer)](IJBMS-18-343-g006){#F4}

Surface area of atherosclerotic plaque: The thoracic aorta of control animals (group A) had no evidence of atherosclerotic plaques. In hypercholesterolemic rabbits (group B), the surface area of the plaques was increased significantly (*P*-value\<0.005). By contrast, the atherosclerotic plaque cross-sectional areas obtained from vessels of hypercholesterolemic animals received HDL of egg yolk supplementation (groups C & D) were reduced in comparison to those from animals that received the cholesterol diet alone (*P*-value \<0.005) ([Figure 5](#F5){ref-type="fig"}).

![Mean of surface area of atherosclerotic plaque (mm^2^) in five groups of A, B, C, D, and E. Group A: normal group, B: only atherosclerotic, C: atherosclerotic and gavaged dose 1, D: atherosclerotic and gavaged dose 2, E: only gavaged dose 3. Values are expressed as mean ±SEM. \*\*\**P*-value \< 0.001 and \#\#\#*P*-value \< 0.001 (\*versus group A) (\#versus group B)](IJBMS-18-343-g007){#F5}

Discussion {#sec1-4}
==========

In this study we demonstrated by chemical and histological evaluation that egg yolk HDL treatment resulted in a significant decrease in atherosclerotic plaque surface. Treatment with high and low doses of egg yolk HDL (400 and 100 mg/kg) was shown to increase plasma HDL levels. Increased HDL levels are correlated inversely with cardiovascular disease ([@ref11], [@ref12]), but low plasma levels of HDL are associated with increased risk of coronary heart disease (CHD) ([@ref13], [@ref14]). A strong therapeutic rational therefore exists for increasing plasma HDL levels of patients at risk for CHD ([@ref15]). The torcetrapib clinical trial, where patients taking the cholesteryl ester transfer protein (CETP) inhibitor showed an increase of 72% in HDL levels, was terminated prematurely as it resulted in an increased risk of mortality and morbidity of unknown mechanism ([@ref16],[@ref17]).

The present study also demonstrated the antiatherogenic effect of purified HDL from egg yolk on experimental atherosclerosis. In agreement with our study, it was shown that IV injection of the homologous HDL-vHDL fraction suppressed the progression of atherosclerosis in cholesterol-fed rabbits ([@ref18]).

This study provides the first data that purified HDL egg yolk has an anti-atherogenic effect in experimental model of atherosclerosis. One of the important findings in our study is that egg yolk HDL does significantly affect plasma cholesterol and HDL plasma levels and does significantly decrease cholesterol content in the vascular walls which can inhibit the progression of atherosclerosis ([@ref11], [@ref13], [@ref19]).

Omole and Ighodaro evaluated the effect of egg yolk consumption on the lipid profiles which implied an increase in serum cholesterol ([@ref20]) Spence *et al*, also showed that regular consumption of eggs increases the risk of cardiovascular diseases. But in our study the HDL separated from egg yolk by the methods mentioned has lost a high percentage of fat in the egg yolks in the final product. It seems that the high percentage of HDL can impinge anti- atherogenic effect and reduce the atherosclerotic plaque size ([@ref19], [@ref21]). In turn, the aim of this study was to purify the HDL from egg yolk that could produce large amounts of HDL for determining the oral effects. In our knowledge this is the first report on the preventive effect of the HDL egg yolk on lipid profile and atherosclerotic plaque size in an animal model.

The cardio-protective effects of HDL have become the topic of intense scientific scrutiny in recent years. One of the hypotheses suggested the key role of HDL in reversing cholesterol transport pathway ([@ref22], [@ref23]). On the other hand a high level of plasma HDL promotes the net movement of cholesterol from extra hepatic tissues back to the liver; consequently, reduction of the cholesterol accumulation was seen in peripheral tissues. This process may finally decrease athero-sclerosis. The metabolic fate of HDL-associated cholesterol through the reverse cholesterol transport pathway is intimately linked to the metabolism of TG-rich lipoproteins ([@ref23]). Indeed, one mechanism whereby the cholesteryl esters carried initially within the HDL particles are transported to the liver is through transferring to apo B-containing lipoproteins by CETP ([@ref24]) with the eventual uptake of these lipoproteins within hepatocytes ([@ref25], [@ref26]).

HDL has also been shown to promote fibrinolysis ([@ref27], [@ref28]), to act as an anti-oxidant ([@ref29], [@ref30]) and to decrease LDL uptake in endothelial cells by challenging for the LDL receptor ([@ref31], [@ref32]).

Thus, the extent to which the reverse cholesterol transport pathway is involved in protecting against atherosclerosis remains to be clearly recognized, and it have to be mentioned that other antiatherogenic properties of HDL may also play an important function in this process ([@ref22]). Plasma concentrations of HDL cholesterol and apo A-I, the major protein moiety of HDL are inversely correlated by plasma TG concentrations ([@ref33], [@ref34], [@ref23]).

Conclusion {#sec1-5}
==========

Our findings indicated that treatment with egg yolk HDL increased serum HDL-C and decreased atherosclerotic plaque size in rabbits. Thus, egg yolk HDL can be considered as an anti-atherosclerotic agent in treatment of patients with CVD.
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